Life Science Industry Leaders Gather to Advance Global Clinical Outcomes

New York - The Conference Forum has announced that the 3^rd Annual Executing Global Clinical Trial’s event will take place on September 13-14 at the Fairmont Copley Square Hotel in Boston, MA.  “The trend to globalization creates opportunities and challenges for clinical trial management.  To be successful, we must focus on quality, ethics, fair market value, logistics and culture,” says Dr Barbara Skinn, Director of Collaborative Science Center of Excellence at Bristol-Myers Squibb.

Research Triangle Park, N.C. – Copernicus Group IRB (CGIRB), a leading independent institutional review board, today announced the selection of IRB Chairperson Glenn Veit as a speaker for the May 15 “Creating a Global Clinical Trial Platform” symposium. The event is sponsored by the Drug Information Association and the Duke Clinical Research Institute in collaboration with CGIRB.

Veit, a frequent industry speaker, and his co-panelists from Duke Medicine, Harvard University and Duke University Health System IRB, will discuss the practical implications and ethical considerations for multisite clinical trials conducted in a global setting during their session titled “Globalization of Clinical Research: Emerging Issues for Sponsors, Academic Research.” The panelists will provide strategies for sponsors, Academic Research Organizations and IRBs to work collaboratively to ensure the quality of global clinical trials.

Y-Prime Technologies LLC, a premier eClinical products and consulting company, is introducing two new software solutions, Prime eMVR™ and Prime IxR ™ that will optimize management and enhance performance of global clinical trials.
“For years, our consulting business has thrived providing high level integration and customization expertise leveraging our experience in both biopharmaceutical research and information technology,” explains Y-Prime CEO Shawn Blackburn.  “Today, we are introducing the first two eClinical products that leverage these unparalleled capabilities providing smooth integration with existing systems, highly reliable data interchange and far-more efficient reporting tools that can save any biopharmaceutical company millions of dollars.”